Last reviewed · How we verify
NCT05304143: Claustro-VIR
Efficacy of Immersive Entertainement Glasses in Magnetic Resonance Imaging (MRI)
NA trial testing Virtual Immersive Reality Glasses in Claustrophobia in 206 participants. Completed in 3 November 2022.
3 November 2022
Quick facts
| Lead sponsor | Hospital Mutua de Terrassa |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 206 |
| Start date | 1 January 2022 |
| Primary completion | 3 November 2022 |
| Estimated completion | 3 November 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Virtual Immersive Reality Glasses
- Conventional nurse support
Conditions studied
- Claustrophobia — all drugs for Claustrophobia →
- Magnetic Resonance Imaging (MRI) — all drugs for Magnetic Resonance Imaging (MRI) →
Sponsor
Hospital Mutua de Terrassa
Who can join
Adults 18 to 90, any sex, with Claustrophobia or Magnetic Resonance Imaging (MRI). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Claustrophobia is the most common type of specific phobia, and in the context of performing an MRI, it leads to premature completion of the test or a sedation. According to some authors, 1,6% of the patients terminated the test prematurely due to claustrophobia, and, in addition, 3.8% underwent conscious sedation. These procedures increase the risk of complications, and the cost of care. The use of anxiolytics is an option to reduce anxiety, but these drugs carry the possibility of suffering adverse effects, and the fact that patients cannot drive home when the MRI is finished. For these reasons, it is especially relevant to determine which non-pharmacological interventions are most effective, and among them, the use of Immersive Entertainment Glasses is a low-interventionist option that can help to overcome fear of the test. Objective: To determine the effectiveness of Immersive Entertainment Glasses in the success of the performance of an MRI and in the reduction of anxiety levels, in patients who express having claustrophobia. Methodology: Design: Clinical trial with intervention and control group. Participants: patients who define themselves as claustrophobic and should have an MRI. The sample will be made up of 206 individuals, divided between an intervention group and a control group. expecting a 20% difference between the success of the test of the control and intervention group subjects. People who meet the inclusion criteria will be distributed into the control or intervention group. The intervention group will use the Immersive Entertainment Glasses to perform the MRI and the control group will have the support of the nurse through educational techniques. Expected results: the success rate in performing MRIs is expected to increase by 20%, thanks to the use of Immersive Entertainment Glasses. Expected duration: 12 months, or until obtaining the expected sample.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Claustrophobia in magnetic resonance imaging: A randomised controlled trial of immersive entertainment glasses.
Diaz-Membrives M, Garrido-Ribas I, Caro-Benito C, Font-Cabrera C, et al · · 2026 · PMID 41485316 · DOI 10.1016/j.radi.2025.103318
Verify or expand the search:
- PubMed search for NCT05304143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Claustrophobia
Currently open trials in the same condition.
- NCT07296822 — Internet-Based Cognitive Behavioral Therapy for MRI-Related Anxiety · NA · recruiting
- NCT05876117 — Premedication for Claustrophobic Patients for MRI Scan · recruiting
Other Hospital Mutua de Terrassa trials
Trials by the same sponsor.
- NCT07070596 — Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-ce · recruiting
- NCT06404931 — Transvaginal Human Acellular Dermal Matrix for Prolapse Treatment · Phase 2 · recruiting
- NCT05919433 — Detection Program for Patients With Primary Biliary Cholangitis Lost in the System · recruiting
- NCT06036680 — Long-term Study of Endoscopic Treatment of Stenosis in Crohn´s Disease · unknown
- NCT05708820 — Online Education Programme for People With Type 1 Diabetes and Suboptimal Metabolic Control · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05304143 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Mutua de Terrassa
- Last refreshed: 25 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05304143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing